{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-26-000042","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2026-07-30T20:18:32+00:00","discovered_at":"2026-07-30T20:19:10.319899+00:00","generated_at":"2026-07-30T20:19:16.906309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veracyte Q2 revenue up 15% to $150.3M; launches Prosigna and TrueMRD","bullets":["Total revenue $150.3M (+15% YoY); testing revenue $145.7M (+19%); Decipher +20%, Afirma +18%.","GAAP net income $25.5M (17% of revenue); adjusted EBITDA $44.0M (29.2% of revenue).","Launched Prosigna LDT for early-stage HR+ breast cancer and TrueMRD for MIBC; secured Medicare coverage for TrueMRD.","Cash from ops $45.8M; cash & investments $485.2M as of June 30, 2026.","Total testing volume up 14% to 48,389 tests; Decipher tests +17%, Afirma +10%."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-26-000042","json":"https://secwatch.observer/filing/0001384101-26-000042.json","markdown":"https://secwatch.observer/filing/0001384101-26-000042.md","text":"https://secwatch.observer/filing/0001384101-26-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/0001384101-26-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/vcyt-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:19:16.906309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}